Cargando…

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia

Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roilides, Emmanuel, Carlesse, Fabianne, Tawadrous, Margaret, Leister-Tebbe, Heidi, Conte, Umberto, Raber, Susan, Swanson, Robert, Yan, Jean L., Aram, Jalal A., Queiroz-Telles, Flavio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Williams & Wilkins 2020
Materias:	Antimicrobial Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182240/ https://www.ncbi.nlm.nih.gov/pubmed/32032174 http://dx.doi.org/10.1097/INF.0000000000002568

Ejemplares similares

Safety and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children
por: Roilides, Emmanuel, et al.
Publicado: (2017)

Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis
por: Xie, Rujia, et al.
Publicado: (2020)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies
por: Sganga, Gabriele, et al.
Publicado: (2019)

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials
por: Kullberg, Bart Jan, et al.
Publicado: (2017)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
por: Vianna, Cid Manso de Mello, et al.
Publicado: (2023)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial
por: Roilides, Emmanuel, et al.
Publicado: (2023)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

375. Tolerability of Anidulafungin for Candidemia in Patients With Hepatic or Renal Dysfunction
por: Kim, Ji Young, et al.
Publicado: (2018)

Micafungin in Premature and Non-premature Infants: A Systematic Review of 9 Clinical Trials
por: Manzoni, Paolo, et al.
Publicado: (2014)

Determinants of fluconazole resistance and echinocandin tolerance in C. parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU
por: Daneshnia, Farnaz, et al.
Publicado: (2022)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
por: Vazquez, Jose, et al.
Publicado: (2014)

Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies
por: De Rosa, Francesco Giuseppe, et al.
Publicado: (2021)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
por: Ruhnke, M, et al.
Publicado: (2012)

N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro
por: Lackner, Michaela, et al.
Publicado: (2022)

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
por: Auzinger, Georg, et al.
Publicado: (2015)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

2111. Anidulafungin vs. Micafungin Treatment in Adult Patients with Candidemia: A Retrospective Study of Single-Center Experience
por: Suh, Jinwoong, et al.
Publicado: (2019)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
por: Martin, Judith M., et al.
Publicado: (2017)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study
por: Hasan, Md Jahidul, et al.
Publicado: (2022)

Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
por: Mootsikapun, Piroon, et al.
Publicado: (2013)

Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
por: Lee, Bonny, et al.
Publicado: (2017)

Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece
por: Galani, Irene, et al.
Publicado: (2012)

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
por: Syriopoulou, Vassiliki, et al.
Publicado: (2016)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study
por: Alter, Sherman J., et al.
Publicado: (2019)

Exploiting Homoplasy in Genome-Wide Association Studies to Enhance Identification of Antibiotic-Resistance Mutations in Bacterial Genomes
por: Lai, Yi-Pin, et al.
Publicado: (2020)

A Novel Cecropin D-Derived Short Cationic Antimicrobial Peptide Exhibits Antibacterial Activity Against Wild-Type and Multidrug-Resistant Strains of Klebsiella pneumoniae and Pseudomonas aeruginosa
por: Ocampo-Ibáñez, Iván Darío, et al.
Publicado: (2020)

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)
por: Baker, Jeffrey, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

Draft Genome Sequence of Ciprofloxacin and Ceftriaxone Resistant Campylobacter jejuni MM26-781 Assigned to Novel ST Isolated From Common Pigeon in Lithuania
por: Aksomaitiene, Jurgita, et al.
Publicado: (2019)

Molecular Docking of Broad-Spectrum Antibodies on Hemagglutinins of Influenza A Virus
por: Le, Khanh PB, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_te26oa2gl4l91cp7b147n4chhq